Literature DB >> 25895963

Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome.

Mondo Kuroda1, Masaki Shimizu2, Natsumi Inoue1, Iku Ikeno1, Hiroyasu Nakagawa1, Ayano Yokoi1, Yo Niida3, Michio Konishi4, Hisashi Kaneda5, Noboru Igarashi6, Junya Yamahana7, Hiromichi Taneichi8, Hirokazu Kanegane8, Mika Ito9, Shigeru Saito9, Kengo Furuichi10, Takashi Wada10, Masaru Nakagawa11, Hitoshi Yokoyama11, Akihiro Yachie1.   

Abstract

Tau protein levels in cerebrospinal fluid (CSF) and serum are elevated in patients with various central nervous system diseases. We investigated whether serum tau protein levels are useful for predicting and assessing disease activity of acute encephalopathy (AE) in enterohemorrhagic Escherichia coli (EHEC) O111-induced hemolytic uremic syndrome (HUS; EHEC encephalopathy). Serum samples were obtained from 14 patients with EHEC O111/HUS, 20 patients with non-EHEC-related AE, and 20 age- and sex-matched healthy controls. CSF samples were obtained from 2 patients with EHEC encephalopathy and 20 patients with non-EHEC-related AE. Tau protein levels and levels of several proinflammatory cytokines were quantified by enzyme-linked immunosorbent assays. Results were compared with the clinical features of EHEC encephalopathy, including magnetic resonance image (MRI) findings. Serum tau levels in patients with EHEC encephalopathy were significantly elevated compared with those in patients with EHEC O111/HUS without encephalopathy, patients with non-EHEC-related AE, and healthy controls. The ratio of CSF tau levels to serum tau levels was >1.0 in all patients with non-EHEC-related AE but <1.0 in 2 patients with EHEC encephalopathy. Serum tau protein levels increased rapidly and markedly in patients with severe EHEC 0111/HUS and encephalopathy when HUS occurred, but were not elevated in mild patients, even in the HUS phase. Furthermore, changes in serum tau protein levels in patients with EHEC encephalopathy were consistent with abnormalities on brain MRI and were positively correlated with proinflammatory cytokine levels. Our results indicate that serum tau protein might be useful to predict and assess disease activity of EHEC encephalopathy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Encephalopathy; Enterohemorrhagic Escherichia coli; Hemolytic uremic syndrome; Tau protein

Mesh:

Substances:

Year:  2015        PMID: 25895963     DOI: 10.1016/j.neuint.2015.04.003

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

Review 1.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

2.  Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events.

Authors:  Juha Onatsu; Ritva Vanninen; Pekka JÄkÄlÄ; Pirjo Mustonen; Kari Pulkki; Miika Korhonen; Marja Hedman; Kina HÖglund; Kaj Blennow; Henrik Zetterberg; Sanna-Kaisa Herukka; Mikko Taina
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

3.  Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography.

Authors:  Ulrike Löbel; Nils Daniel Forkert; Peter Schmitt; Thorsten Dohrmann; Maria Schroeder; Tim Magnus; Stefan Kluge; Christina Weiler-Normann; Xiaoming Bi; Jens Fiehler; Jan Sedlacik
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

4.  Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome.

Authors:  Yuko Tasaki; Natsumi Inoue; Masaki Shimizu; Naotoshi Sugimoto; Sayaka Ishikawa; Mao Mizuta; Tadafumi Yokoyama; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie; Taizo Wada
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

5.  Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli.

Authors:  Jorge Goldstein; Krista Nuñez-Goluboay; Alipio Pinto
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

6.  The critical role of lipopolysaccharide in the upregulation of aquaporin 4 in glial cells treated with Shiga toxin.

Authors:  Naotoshi Sugimoto; Hue Leu; Natsumi Inoue; Masaki Shimizu; Tomoko Toma; Mondo Kuroda; Takekatsu Saito; Taizo Wada; Akihiro Yachie
Journal:  J Biomed Sci       Date:  2015-09-18       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.